|
|||||
|
|
Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine |
|
| Authors: | Stewart J. Tepper MD FAHS Yan Dong PhD Maurice Vincent MD PhD Linda A. Wietecha BS MSN |
| Affiliation: | 1. Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA;2. Eli Lilly and Company, and/or one of its subsidiaries, Indianapolis, Indiana, USA |
| Abstract: | |
| Keywords: | 50% response calcitonin gene-related peptide galcanezumab migraine migraine headache days prevention |